Human epidermal growth factor receptor-2 (HER 2) positive breast cancers represent a highly aggressive cancer subtype and are associated witha worse prognosis. They tend to be more with lower survival rates but better prognosis than the triple-negative subtype.

Lung cancer is the leading cause of cancer-related death. Despite a number of studies that have provided prognostic biomarkers for lung cancer, a paucity of reliable markers and therapeutic targets exist to diagnose and treat this aggressive disease. In this study we investigated the potential of nuclear receptors (NRs), many of which are well-established drug targets, as therapeutic markers in...

Gastrointestinal (GI) cancers that include all of the digestive tract organs are generally associated with obesity, lack exercising, smoking, poor diet, and heavy alcohol consumption. Treatment GI typically involves surgery followed by chemotherapy and/or radiation. Unfortunately, intrinsic or acquired resistance to these therapies underscore need for more effective targeted have been proven in...

Although long-term clinical use of progestins is associated with an increased incidence of breast cancers, their role in established cancers is unclear. Estrogens are considered to be the main mitogens in the majority of breast cancers. Whether progesterone affects proliferation and/or differentiation is under debate. To assess the role of progesterone in established breast cancers, we used T47...

background : this study evaluates estrogen and progesterone expressions in patients with ovarian tumors (both benign and malignant) and their correlation with various clinicopathological prognostic parameters. receptors for estrogen and progesterone are predictive and prognostic markers of endometrial and breast cancers. however, their clinical significance in epithelial ovarian cancer is not c...

PURPOSE Resistance to anti-HER2 monoclonal antibody trastuzumab is a relevant issue in breast cancer patients. Among the mechanisms implicated in trastuzumab resistance, increasing evidence supports a role of tumor microenvironment. We previously found that a novel toll-like receptor 9 agonist, referred to as immune modulatory oligonucleotide (IMO) and currently under clinical investigation, ac...

Neurotensin receptor 1 (NTS1) is involved in the development and progression of numerous cancers, which makes it an interesting target for diagnostic therapeutic agents. A small molecule NTS1 antagonist, named [177Lu]Lu-IPN01087, currently evaluated phase I/II clinical trials targeted therapy neurotensin receptor-positive cancers. In this study, we synthesized seven compounds based on structure...

Neuroblastomas are the most common extracranial solid tumors in children and have a unique feature of neuronal differentiation. Peroxisome proliferator-activated receptor (PPAR)-γ is reported to neuroprotective effects addition having antitumor various cancers. Thus, we aimed clarify role PPAR-γ agonist antagonist malignant neuroblastomas, which also possess features. In MYCN-amplified neurobla...